Literature DB >> 5934378

Megaloblastic anaemia during methotrexate treatment of psoriasis.

P Borrie, P A Clark.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5934378      PMCID: PMC1844910          DOI: 10.1136/bmj.1.5499.1339

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  5 in total

1.  PARENTERAL VS. ORAL FOLIC ACID ANTAGONISTS.

Authors:  R AUERBACH
Journal:  Arch Dermatol       Date:  1964-12

2.  FOLIC ACID ANTAGONIST. EFFECTS ON THE CELL AND THE PATIENT. COMBINED CLINICAL STAFF CONFERENCE AT THE NATIONAL INSTITUTES OF HEALTH.

Authors:  N I BERLIN; D RALL; J A MEAD; E J FREIREICH; E VANSCOTT; R HERTZ; M B LIPSETT
Journal:  Ann Intern Med       Date:  1963-12       Impact factor: 25.391

3.  PARENTERAL METHOTREXATE IN PSORIASIS.

Authors:  E J VANSCOTT; R AUERBACH; G D WEINSTEIN
Journal:  Arch Dermatol       Date:  1964-04

4.  METHOTREXATE DISPLACEMENT IN MAN.

Authors:  D G JOHNS; J W HOLLINGSWORTH; A R CASHMORE; I H PLENDERLEITH; J R BERTINO
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

5.  THE TREATMENT OF PSORIASIS WITH FOLIC ACID ANTAGONISTS.

Authors:  T J RYAN; H R VICKERS; S N SALEM; S T CALLENDER; J BADENOCH
Journal:  Br J Dermatol       Date:  1964-12       Impact factor: 9.302

  5 in total
  2 in total

Review 1.  Drugs and vitamin deficiency.

Authors:  L Ovesen
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

2.  The effect of high dosage of methotrexate, associated with folinic acid, on the suppression of tuberculin sensitivity in guinea-pigs.

Authors:  P D Hart; R J Rees; J S Niven
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.